Teduglutide

Also known as: Gattex, Revestive, GLP-2 analog

Teduglutide is a recombinant analog of glucagon-like peptide-2 (GLP-2) that acts as a selective GLP-2 receptor agonist. Its primary mechanism involves binding to GLP-2 receptors in the gastrointestinal tract, which stimulates crypt cell proliferation and reduces enterocyte apoptosis, leading to increased intestinal mucosal growth, enhanced absorptive surface area, and improved fluid and nutrient absorption. Additionally, it slows gastric emptying and reduces intestinal motility, further supporting nutrient retention. Key research findings from clinical trials demonstrate that teduglutide significantly reduces parenteral nutrition volume requirements in patients with short bowel syndrome (SBS). In pivotal Phase III studies (e.g., NCT00798967), 63% of treated patients achieved a ≥20% reduction in parenteral support volume by week 24, with sustained effects over 12 months. Long-term extension studies confirm maintained intestinal adaptation and reduced dependence on intravenous support, though adverse effects include gastrointestinal obstruction, gallbladder disease, and fluid overload. Clinically, teduglutide is approved for adults and pediatric patients (≥1 year) with SBS who require parenteral support. It is administered subcutaneously once daily and is associated with improved quality of life and reduced hospitalization rates. Monitoring for potential neoplastic growth (due to trophic effects) and pancreaticobiliary complications is recommended. For research purposes only — not medical advice.

Key data

Research & studies

Frequently asked questions

Related peptides